Leveraging big data of immune checkpoint blockade response identifies novel potential targets von Bareche, Y., Kelly, D., Abbas-Aghababazadeh, F., Nakano, M., Esfahani, P.N., Tkachuk, D., Mohammad, H., Samstein, R., Lee, C.-H., Morris, L.G.T., Bedard, P.L., Haibe-Kains, B., Stagg, J.

Volltext

A phase II study of axitinib (AG-013736) in patients with incurable adenoid cystic carcinoma von Ho, A.L., Dunn, L., Sherman, E.J., Fury, M.G., Baxi, S.S., Chandramohan, R., Dogan, S., Morris, L.G.T., Cullen, G.D., Haque, S., Sima, C.S., Ni, A., Antonescu, C.R., Katabi, N., Pfister, D.G.

Volltext

Panel-based estimates of tumor mutational burden: characterizing unknown unknowns von Yang, W., Morris, L.G.T., Chan, T.A.

Volltext

Tumor and Blood B Cell Abundance Outperforms Established Immune Checkpoint Blockade Response Prediction Signatures in Head and Neck Cancer von Chang, T.-G., Spathis, A., Schäffer, A.A., Gavrielatou, N., Kuo, F., Jia, D., Mukherjee, S., Sievers, C., Economopoulou, P., Anastasiou, M., Moutafi, M., Pal, L.R., Vos, J., Lee, A.S., Lam, S., Zhao, K., Jiang, P., Allen, C.T., Foukas, P., Gomatou, G., Altan-Bonnet, G., Morris, L.G.T., Psyrri, A., Ruppin, E.

Volltext

Selective use of radioactive iodine (RAI) in thyroid cancer: no longer “one size fits all” von Marti, Jennifer L., MD, Morris, Luc G.T., MD, MSc, Ho, Allen S., MD

Volltext

Genetic determinants at the interface of cancer and neurodegenerative disease von Morris, L G T, Veeriah, S, Chan, T A

Volltext

Reply to: Radioiodine ablation necessary for patients with low-risk papillary thyroid carcinoma and tumor >4 cm? von Marti, J.L., Morris, L.G.T., Ho, A.S.

Volltext

Eyelash trichomegaly secondary to panitumumab therapy von Morris, L G T, Hochster, H S, Delacure, M D

Volltext

Clinical-genomic determinants of immune checkpoint blockade response in head and neck squamous cell carcinoma von Valero, C., Golkaram, M., Vos, J.L., Xu, B., Fitzgerald, C., Lee, M., Kaplan, S., Han, C.Y., Pei, X., Sarkar, R., Boe, L.A., Pandey, A., Koh, E.S., Zuur, C.L., Solit, D.B., Pawlowski, T., Liu, L., Ho, A.L., Chowell, D., Riaz, N., Chan, T.A., Morris, L.G.T.

Volltext bestellen

Nivolumab plus ipilimumab in advanced salivary gland cancer: a phase 2 trial von Vos, J.L., Burman, B., Jain, S., Fitzgerald, C.W.R., Sherman, E.J., Dunn, L.A., Fetten, J.V., Michel, L.S., Kriplani, A., Ng, K.K., Eng, J., Tchekmedyian, V., Haque, S., Katabi, N., Kuo, F.S., Han, C.Y., Nadeem, Z., Yang, W., Makarov, V., Srivastava, R.M., Ostrovnaya, I., Prasad, M., Zuur, C.L., Riaz, N., Pfister, D.G., Klebanoff, C.A., Chan, T.A., Ho, A.L., Morris, L.G.T.

Volltext bestellen